HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance

Advances in Pharmacology

Volumn 65, Issue , 2012, Pages 471-517

  Jhaveri, Komal ^a,b   Modi, Shanu ^a,c  

^a NEW YORK UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Biomarkers; Client proteins; Drug resistance; HSP90; Pharmacodynamic assays; Pharmacokinetics

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; 5422; ALVESPIMYCIN; AT 13387; BIIB 021; BIOLOGICAL MARKER; CISPLATIN; CNF 2024; CUDC 305; CYTARABINE; DOCETAXEL; DS 2248; GANETESPIB; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HSP 990; IPI 493; IRINOTECAN; KW 2478; MPC 3100; PU H71; PURINE; PURINE DERIVATIVE; RESORCINOL; RETASPIMYCIN; SNX 5422; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG; VER 52269; XL 888;

ACIDOSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLURRED VISION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CASTRATE REFRACTORY PROSTATE CANCER; CHONDROSARCOMA; CYTOTOXICITY; DIAGNOSTIC PROCEDURE; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRY EYE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; HUMAN; HYPOTENSION; KERATITIS; KIDNEY CANCER; KIDNEY DISEASE; KIDNEY FAILURE; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; NONHUMAN; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 84865839031     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397927-8.00015-4     Document Type: Chapter

References (169)

1. Akhurst T., Morris P., Modi S., Carraquillo J., Solit D., Hudis C., et al. Positron emission tomography (PET) with radiolabeled F(ab')2-trastuzumab fragments in patients (pts) with HER2-positive metastatic breast cancer (MBC): initial feasibility results. Breast Cancer Symposium 2008.
2. Ali M.M., Roe S.M., Vaughan C.K., Meyer P., Panaretou B., Piper P.W., et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006, 440:1013-1017.
3. Arlander S.J., Eapen A.K., Vroman B.T., McDonald R.J., Toft D.O., Karnitz L.M. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. The Journal of Biological Chemistry 2003, 278:52572-52577.
4. Azoitei N., Hoffmann C.M., Ellegast J.M., Ball C.R., Obermayer K., Gossele U., et al. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. The Journal of Experimental Medicine 2012, 209:697-711.
5. Bagatell R., Paine-Murrieta G.D., Taylor C.W., Pulcini E.J., Akinaga S., Benjamin I.J., et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clinical Cancer Research 2000, 6:3312-3318.
6. Bagatell R., Beliakoff J., David C.L., Marron M.T., Whitesell L. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. International Journal of Cancer 2005, 113:179-188.
7. Bagatell R., Gore L., Egorin M.J., Ho R., Heller G., Boucher N., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clinical Cancer Research 2007, 13:1783-1788.
8. Banerji U., O'Donnell A., Scurr M., Pacey S., Stapleton S., Asad Y., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. Journal of Clinical Oncology 2005, 23:4152-4161.
9. Basso A.D., Solit D.B., Munster P.N., Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002, 21:1159-1166.
10. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:20932-20937.
11. Bergstrom M., Monazzam A., Razifar P., Ide S., Josephsson R., Langstrom B. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922. Journal of Nuclear Medicine 2008, 49:1204-1210.
12. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology 2010, 28:1124-1130.
13. Brahmer, J. K. M., Goldman, J., Paschold, E., Horn, L., Kepros, J., Teofilovici, F., et al. (2011). A phase 2 study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced NSCLC, presented at the IASLC 14th World Conference on Lung Cancer.
14. Bryson J., Infante J.R., Ramanathan R.K., Jones S.F., Von Hoff D.D., Burris H.A. A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422. Journal of Clinical Oncology 2008, 26. abstract 14613.
15. Caldas-Lopes E., Cerchietti L., Ahn J.H., Clement C.C., Robles A.I., Rodina A., et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:8368-8373.
16. Castro J.E., Prada C.E., Loria O., Kamal A., Chen L., Burrows F.J., et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 2005, 106:2506-2512.
17. Cerchietti L.C., Lopes E.C., Yang S.N., Hatzi K., Bunting K.L., Tsikitas L.A., et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nature Medicine 2009, 15:1369-1376.
18. Chan C., Scollard D.A., McLarty K., Smith S., Reilly R.M. A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. EJNMMI Research 2011, 1:15.
19. Chandarlapaty S., Sawai A., Ye Q., Scott A., Silinski M., Huang K., et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clinical Cancer Research 2008, 14:240-248.
20. Chandarlapaty S., Scaltriti M., Angelini P., Ye Q., Guzman M., Hudis C.A., et al. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 2010, 29:325-334.
21. Chang D.Z., Panageas K.S., Osman I., Polsky D., Busam K., Chapman P.B. Clinical significance of BRAF mutations in metastatic melanoma. Journal of Translational Medicine 2004, 2:46.
22. Chiosis G., Timaul M.N., Lucas B., Munster P.N., Zheng F.F., Sepp-Lorenzino L., et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chemistry & Biology 2001, 8:289-299.
23. Chiosis G., Lucas B., Shtil A., Huezo H., Rosen N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorganic & Medicinal Chemistry 2002, 10:3555-3564.
24. Cho D., Heath E.I., Cleary J.M., Kwak E.L., Gandhi L., Lawrence D.P., et al. A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: updated report. Journal of Clinical Oncology 2011, 29. Abstract 3051.
25. Citri A., Gan J., Mosesson Y., Vereb G., Szollosi J., Yarden Y. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Reports 2004, 5:1165-1170.
26. Conde R., Belak Z.R., Nair M., O'Carroll R.F., Ovsenek N. Modulation of Hsf1 activity by novobiocin and geldanamycin. Biochemistry and Cell Biology 2009, 87:845-851.
27. Cowen L.E., Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005, 309:2185-2189.
28. Cowen L.E., Singh S.D., Kohler J.R., Collins C., Zaas A.K., Schell W.A., et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:2818-2823.
29. Cunningham J.J., Gatenby R.A., Brown J.S. Evolutionary dynamics in cancer therapy. Molecular Pharmaceutics 2011, 8:2094-2100.
30. Dakappagari N., Neely L., Tangri S., Lundgren K., Hipolito L., Estrellado A., et al. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers 2010, 15:31-38.
31. Day J.E., Sharp S.Y., Rowlands M.G., Aherne W., Lewis W., Roe S.M., et al. Inhibition of Hsp90 with resorcylic acid macrolactones: synthesis and binding studies. Chemistry 2010, 16:10366-10372.
32. DeBoer C., Meulman P.A., Wnuk R.J., Peterson D.H. Geldanamycin, a new antibiotic. Journal of Antibiotics 1970, 23:442-447.
33. Demetri G., Sledge G., Morgan J.A., Wagner A., Quigley M.T., Polson K., et al. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: updated results of a phase I trial. Journal of Clinical Oncology, ASCO Annual Meetings Proceedings Part I 2007, 25(18S):10024.
34. Donnelly A., Blagg B.S. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Current Medicinal Chemistry 2008, 15:2702-2717.
35. Eiseman J.L., Guo J., Ramanathan R.K., Belani C.P., Solit D.B., Scher H.I., et al. Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. Clinical Cancer Research 2007, 13:2121-2127.
36. Elfiky A., Saif M.W., Beeram M., O'Brien S., Lammanna N., Castro J.E., et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience. Journal of Clinical Oncology 2008, 26. abstract 2503.
37. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
38. Evans C.G., Chang L., Gestwicki J.E. Heat shock protein 70 (hsp70) as an emerging drug target. Journal of Medicinal Chemistry 2010, 53:4585-4602.
39. Fedier A., Stuedli A., Fink D. Presence of MLH1 protein aggravates the potential of the HSP90 inhibitor radicicol to sensitize tumor cells to cisplatin. International Journal of Oncology 2005, 27:1697-1705.
40. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nature Reviews Genetics 2006, 7:21-33.
41. Flaherty K., Gore L., Avadhani A., Leong S., Harlacker K., Zhong Z. Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): two different schedules in patients with advanced malignancies. Journal of Clinical Oncology 2007, 25.
42. Flatten K., Dai N.T., Vroman B.T., Loegering D., Erlichman C., Karnitz L.M., et al. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. The Journal of Biological Chemistry 2005, 280:14349-14355.
43. Francis L.K., Alsayed Y., Leleu X., Jia X., Singha U.K., Anderson J., et al. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clinical Cancer Research 2006, 12:6826-6835.
44. Gallegos Ruiz M.I., Floor K., Roepman P., Rodriguez J.A., Meijer G.A., Mooi W.J., et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 2008, 3:e0001722.
45. Gaspar N., Sharp S.Y., Pacey S., Jones C., Walton M., Vassal G., et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Research 2009, 69:1966-1975.
46. Georgakis G.V., Li Y., Rassidakis G.Z., Martinez-Valdez H., Medeiros L.J., Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clinical Cancer Research 2006, 12:584-590.
47. George P., Bali P., Cohen P., Tao J., Guo F., Sigua C., et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Research 2004, 64:3645-3652.
48. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005, 105:1768-1776.
49. Goetz M.P., Toft D., Reid J., Ames M., Stensgard B., Safgren S., et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Journal of Clinical Oncology 2005, 23:1078-1087.
50. Grem J.L., Morrison G., Guo X.D., Agnew E., Takimoto C.H., Thomas R., et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. Journal of Clinical Oncology 2005, 23:1885-1893.
51. Hadchity E., Aloy M.T., Paulin C., Armandy E., Watkin E., Rousson R., et al. Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma. Molecular Therapy 2009, 17:1387-1394.
52. Heath E.I., Hillman D.W., Vaishampayan U., Sheng S., Sarkar F., Harper F., et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clinical Cancer Research 2008, 14:7940-7946.
53. Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Research 2003, 63:5198-5202.
54. Holland J.P., Caldas-Lopes E., Divilov V., Longo V.A., Taldone T., Zatorska D., et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One 2010, 5:e8859.
55. Hollingshead M., Alley M., Burger A.M., Borgel S., Pacula-Cox C., Fiebig H.H., et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemotherapy and Pharmacology 2005, 56:115-125.
56. Hubbard J., Erlichman C., Toft D.O., Qin R., Stensgard B.A., Felten S., et al. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Investigational New Drugs 2011, 29:473-480.
57. Infinity. A phase 1 dose escalation study of IPI-493. Available from Updated June 10, 2011 [cited; Available from http://clinicaltrials.gov/ct2/show/NCT00724425%3fterm%3dIPI-493%26rank%3d1.
58. Janin Y.L. ATPase inhibitors of heat-shock protein 90, second season. Drug Discovery Today 2010, 15:342-353.
59. Jarosz D.F., Lindquist S. Hsp90 and environmental stress transform the adaptive value of natural genetic variation. Science 2010, 330:1820-1824.
60. Jarosz D.F., Taipale M., Lindquist S. Protein homeostasis and the phenotypic manifestation of genetic diversity: principles and mechanisms. Annual Review of Genetics 2010, 44:189-216.
61. Jhaveri, K. C. S., Lake, D., Gilewski, T., Robson, M., Goldfarb, S., Drullinsky, P., et al. (2011). A phase II trial of ganetespib: efficacy and safety in patients (pts) with metastatic breast cancer (MBC), presented at the 34th San Antonio Breast Cancer Conference in December, 2011.
62. Jhaveri K., Taldone T., Modi S., Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochimica et Biophysica Acta 2012, 1823:742-755.
63. Johnston, A., Allaire, M. (2009). Infinity Halts RING trial in advanced gastrointestinal stromal tumors. Available from http://investoripicom/releasedetailcfm%3fReleaseID%3d377328.
64. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
65. Kaufmann S.H., Karp J.E., Litzow M.R., Mesa R.A., Hogan W., Steensma D.P., et al. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica 2011, 96:1619-1626.
66. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clinical Cancer Research 2006, 12:5764-5769.
67. Kummar S., Gutierrez M.E., Gardner E.R., Chen X., Figg W.D., Zajac-Kaye M., et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. European Journal of Cancer 2010, 46:340-347.
68. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935.
69. Lancet J., Smith D., Bradley R., Komrokji R.S., Teofilovici F., Rizzieri D. A phase I/II trial of the potent Hsp90 inhibitor STA-9090 administered once weekly in patients with advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 2010, 116. Abstract 3294.
70. Lancet J.E., Gojo I., Burton M., Quinn M., Tighe S.M., Kersey K., et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010, 24:699-705.
71. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. Journal of Clinical Oncology 2009, 27:5459-5468.
72. Liao Z.Y., Zhang S.H., Zhen Y.S. Synergistic effects of geldanamycin and antitumor drugs. Yao xue xue bao 2001, 36:569-575.
73. Lu X., Xiao L., Wang L., Ruden D.M. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochemical Pharmacology 2011.
74. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine 2004, 350:2129-2139.
75. Marubayashi S., Koppikar P., Taldone T., Abdel-Wahab O., West N., Bhagwat N., et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. Journal of Clinical Investigation 2010, 120:3578-3593.
76. Matthews S.B., Vielhauer G.A., Manthe C.A., Chaguturu V.K., Szabla K., Matts R.L., et al. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. The Prostate 2010, 70:27-36.
77. McCollum A.K., Teneyck C.J., Sauer B.M., Toft D.O., Erlichman C. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Research 2006, 66:10967-10975.
78. McCollum A.K., Lukasiewicz K.B., Teneyck C.J., Lingle W.L., Toft D.O., Erlichman C. Cisplatin abrogates the geldanamycin-induced heat shock response. Molecular Cancer Therapeutics 2008, 7:3256-3264.
79. Merlo L.M., Pepper J.W., Reid B.J., Maley C.C. Cancer as an evolutionary and ecological process. Nature Reviews Cancer 2006, 6:924-935.
80. Mesa R.A., Loegering D., Powell H.L., Flatten K., Arlander S.J., Dai N.T., et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005, 106:318-327.
81. Messaoudi S., Peyrat J.F., Brion J.D., Alami M. Recent advances in Hsp90 inhibitors as antitumor agents. Anti-Cancer Agents in Medicinal Chemistry 2008, 8:761-782.
82. Mitchell P. Biogen Idec restructures, sharpens neurology focus. Nature Biotechnology 2011, 29(1):7-8.
83. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Fanourakis G., Gu X., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:14374-14379.
84. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Kung A.L., Davies F.E., et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006, 107:1092-1100.
85. Modi S., Stopeck A.T., Gordon M.S., Mendelson D., Solit D.B., Bagatell R., et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. Journal of Clinical Oncology 2007, 25:5410-5417.
86. Modi S., Ismail-Khan R., Munster P., Lucas M., Galluppi G.R., Tangri S., et al. Phase 1 dose-escalation study of the heat shock protein 90 inhibitor BIIB021 with trastuzumab in HER2+ metastatic breast cancer. CTRC-AACR San Antonio Breast Cancer Symposium 2010.
87. Modi S., Saura C., Henderson C.A., Lin N.U., Mahtani R.L., Goddard J., et al. Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer. Journal of Clinical Oncology 2011, 29. abstract 590.
88. Modi S., Stopeck A.T., Linden H.M., Solit D.B., Chandarlapaty S., Rosen N., et al. HSP90 inhibition is effective in breast cancer: a phase 2 trial of tanespimycin (17AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical Cancer Research 2011.
89. Moulick K., Ahn J., Zong H., Rodina A., Chiosis G. A small molecule Hsp90 inhibitor provides a global overview of proteome alterations in cancer. Nature Chemical Biology 2011.
90. Nagengast W.B., de Korte M.A., Oude Munnink T.H., Timmer-Bosscha H., den Dunnen W.F., Hollema H., et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. Journal of Nuclear Medicine 2010, 51:761-767.
91. Nahta R., Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Research: BCR 2006, 8:215.
92. Nguyen D.M., Lorang D., Chen G.A., Stewart JHt, Tabibi E., Schrump D.S. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. The Annals of Thoracic Surgery 2001, 72:371-378. discussion 8-9.
93. Niu G., Cai W., Chen K., Chen X. Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor. Molecular Imaging and Biology: MIB: The Official Publication of the Academy of Molecular Imaging 2008, 10:99-106.
94. Niu G., Li Z., Cao Q., Chen X. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab. European Journal of Nuclear Medicine and Molecular Imaging 2009, 36:1510-1519.
95. Normant E., Paez G., West K.A., Lim A.R., Slocum K.L., Tunkey C., et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011, 30:2581-2586.
96. Nowakowski G.S., McCollum A.K., Ames M.M., Mandrekar S.J., Reid J.M., Adjei A.A., et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clinical Cancer Research 2006, 12:6087-6093.
97. O'Connell M.J., Cimprich K.A. G2 damage checkpoints: what is the turn-on?. Journal of Cell Science 2005, 118:1-6.
98. Oh W., Stadler W.M., Srinivas S., Chu F., Bubley G., Quigley M., et al. A single arm phase II trial of IPI-504 in patients with castration resistant prostate cancer (CRPC). Genitourinary Cancers Symposium 2009, Abstract 219.
99. Oude Munnink T.H., Korte MAd, Nagengast W.B., Timmer-Bosscha H., Schröder C.P., Jong JRd, et al. 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. European Journal of Cancer 2010, 46:678-684.
100. Oxnard G.R., Arcila M.E., Chmielecki J., Ladanyi M., Miller V.A., Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clinical Cancer Research 2011, 17:5530-5537.
101. Pacey S., Wilson R.H., Walton M., Eatock M.M., Hardcastle A., Zetterlund A., et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clinical Cancer Research 2011, 17:1561-1570.
102. Pelicano H., Carew J.S., McQueen T.J., Andreeff M., Plunkett W., Keating M.J., et al. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia 2006, 20:610-619.
103. Peng C., Brain J., Hu Y., Goodrich A., Kong L., Grayzel D., et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007, 110:678-685.
104. Peng C., Li D., Li S. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle 2007, 6:2227-2231.
105. Pfizer. Pfizer annual report. Available from 2008. [cited; Available from http://www.pfizer.com/files/annualreport/2008/financial/financial_highlights2008.pdf.
106. Pick E., Kluger Y., Giltnane J.M., Moeder C., Camp R.L., Rimm D.L., et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Research 2007, 67:2932-2937.
107. Powers M.V., Workman P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Letters 2007, 581:3758-3769.
108. Powers M.V., Jones K., Barillari C., Westwood I., van Montfort R.L., Workman P. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone?. Cell Cycle 2010, 9:1542-1550.
109. Press Release. F. Kosan announces senior management changes and clinical portfolio priorities. Available from 2008. [cited; Available from http://phx.corporate-ir.net/phoenix.zhtml%3fc%3d121014%26p%3dirol-newsArticle%26ID%3d1113760%26highlight%3d.
110. PressRelease. Bristol-Myers Squibb Halts development of tanespimycin. Available from 2008. [cited; Available from http://www.myelomabeacon.com/news/2010/07/22/tanespimycin-development-halted/.
111. Prodromou C., Pearl L.H. Structure and functional relationships of Hsp90. Current Cancer Drug Targets 2003, 3:301-323.
112. Prodromou C., Nuttall J.M., Millson S.H., Roe S.M., Sim T.S., Tan D., et al. Structural basis of the radicicol resistance displayed by a fungal hsp90. ACS Chemical Biology 2009, 4:289-297.
113. Rahmani M., Yu C., Dai Y., Reese E., Ahmed W., Dent P., et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Research 2003, 63:8420-8427.
114. Rajan A., Kelly R.J., Trepel J.B., Kim Y.S., Alarcon S.V., Kummar S., et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clinical Cancer Research 2011, 17:6831-6839.
115. Ramalingam S.S., Egorin M.J., Ramanathan R.K., Remick S.C., Sikorski R.P., Lagattuta T.F., et al. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clinical Cancer Research 2008, 14:3456-3461.
116. Ramanathan R.K., Trump D.L., Eiseman J.L., Belani C.P., Agarwala S.S., Zuhowski E.G., et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clinical Cancer Research 2005, 11:3385-3391.
117. Ramanathan R.K., Egorin M.J., Erlichman C., Remick S.C., Ramalingam S.S., Naret C., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. Journal of Clinical Oncology 2010, 28:1520-1526.
118. Richardson P.G., Badros A.Z., Jagannath S., Tarantolo S., Wolf J.L., Albitar M., et al. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. British Journal of Haematology 2010, 150:428-437.
119. Rodina A., Vilenchik M., Moulick K., Aguirre J., Kim J., Chiang A., et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nature Chemical Biology 2007, 3:498-507.
120. Roforth M.M., Tan C. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells. Anticancer Drugs 2008, 19:681-688.
121. Ronnen E., Kondagunta G., Ishill N., Sweeney S., DeLuca J., Schwartz L., et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Investigational New Drugs 2006, 24:543-546.
122. Rutherford S., Hirate Y., Swalla B.J. The Hsp90 capacitor, developmental remodeling, and evolution: the robustness of gene networks and the curious evolvability of metamorphosis. Critical Reviews in Biochemistry and Molecular Biology 2007, 42:355-372.
123. Samuel T., Sessa C., Britten C., Milligan K.S., Mita M.M., Banerji U., et al. AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies. Journal of Clinical Oncology 2010, 28. Abstract 2528.
124. Sano M. Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons. Neuropharmacology 2001, 40:947-953.
125. Schmidt L., Junker K., Nakaigawa N., Kinjerski T., Weirich G., Miller M., et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999, 18:2343-2350.
126. Schroder C., Pederson J.V., Chua S., Swanton C., Akimov M., Ide S., et al. Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer. Journal of Clinical Oncology 2011, 29.
127. Schulz R., Marchenko N.D., Holembowski L., Fingerle-Rowson G., Pesic M., Zender L., et al. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. The Journal of Experimental Medicine 2012, 209:275-289.
128. Sequist L.V., Gettinger S., Senzer N.N., Martins R.G., Jänne P.A., Lilenbaum R., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. Journal of Clinical Oncology 2010, 28:4953-4960.
129. Shelton S.N., Shawgo M.E., Matthews S.B., Lu Y., Donnelly A.C., Szabla K., et al. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Molecular Pharmacology 2009, 76:1314-1322.
130. Shimamura T., Li D., Ji H., Haringsma H.J., Liniker E., Borgman C.L., et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Research 2008, 68:5827-5838.
131. Shiotsu Y., Neckers L.M., Wortman I., An W.G., Schulte T.W., Soga S., et al. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 2000, 96:2284-2291.
132. Siegelin M.D., Habel A., Gaiser T. 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis. Neurobiology of Disease 2009, 33:243-249.
133. Smith-Jones P.M., Solit D.B., Akhurst T., Afroze F., Rosen N., Larson S.M. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nature Biotechnology 2004, 22:701-706.
134. Smith-Jones P.M., Solit D., Afroze F., Rosen N., Larson S.M. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. Journal of Nuclear Medicine 2006, 47:793-796.
135. Solit D.B., Rosen N. Hsp90: a novel target for cancer therapy. Current Topics in Medicinal Chemistry 2006, 6:1205-1214.
136. Solit D.B., Basso A.D., Olshen A.B., Scher H.I., Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to taxol. Cancer Research 2003, 63:2139-2144.
137. Solit D.B., Ivy S.P., Kopil C., Sikorski R., Morris M.J., Slovin S.F., et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clinical Cancer Research 2007, 13:1775-1782.
138. Solit D., Osman I., Polsky D., Panageas K., Daud A., Goydos J., et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clinical Cancer Research 2008, 14:8302-8307.
139. Sorenson C.M., Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Research 1988, 48:4484-4488.
140. Sreeramulu S., Gande S.L., Gobel M., Schwalbe H. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angewandte Chemie International Edition 2009, 48:5853-5855.
141. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89:239-250.
142. Taldone T., Sun W., Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorganic & Medicinal Chemistry 2009, 17:2225-2235.
143. Tauchi T., Okabe S., Ashihara E., Kimura S., Maekawa T., Ohyashiki K. Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen. Oncogene 2011, 30:2789-2797.
144. Tse A.N., Klimstra D.S., Gonen M., Shah M., Sheikh T., Sikorski R., et al. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clinical Cancer Research 2008, 14:6704-6711.
145. Vaishampayan U.N., Burger A.M., Sausville E.A., Heilbrun L.K., Li J., Horiba M.N., et al. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. Clinical Cancer Research 2010, 16:3795-3804.
146. Vasilevskaya I.A., Rakitina T.V., O'Dwyer P.J. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Research 2003, 63:3241-3246.
147. Vasilevskaya I.A., Rakitina T.V., O'Dwyer P.J. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Molecular Pharmacology 2004, 65:235-243.
148. Vilenchik M., Solit D., Basso A., Huezo H., Lucas B., He H., et al. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chemistry & Biology 2004, 11:787-797.
149. Vincent T.L., Gatenby R.A. An evolutionary model for initiation, promotion, and progression in carcinogenesis. International Journal of Oncology 2008, 32:729-737.
150. Wajant H., Gerspach J., Pfizenmaier K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine & Growth Factor Reviews 2005, 16:55-76.
151. Weigel B.J., Blaney S.M., Reid J.M., Safgren S.L., Bagatell R., Kersey J., et al. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a children's oncology group study. Clinical Cancer Research 2007, 13:1789-1793.
152. Weisberg E., Barrett R., Liu Q., Stone R., Gray N., Griffin J.D. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updates 2009, 12:81-89.
153. Whitesell L., Lin N.U. HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochimica et Biophysica Acta 2012, 1823:756-766.
154. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nature Reviews Cancer 2005, 5:761-772.
155. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., Neckers L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:8324-8328.
156. Williams C.R., Tabios R., Linehan W.M., Neckers L. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. Journal of Urology 2007, 178:1528-1532.
157. Wong C., Chen S. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance. Cancer Research 2009, 69:8670-8677.
158. Workman P., Burrows F., Neckers L., Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Annals of the New York Academy of Sciences 2007, 1113:202-216.
159. Yang S., Qu S., Perez-Tores M., Sawai A., Rosen N., Solit D.B., et al. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Research 2006, 66:6990-6997.
160. Yano A., Tsutsumi S., Soga S., Lee M.J., Trepel J., Osada H., et al. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:15541-15546.
161. Yao Q., Nishiuchi R., Li Q., Kumar A.R., Hudson W.A., Kersey J.H. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clinical Cancer Research 2003, 9:4483-4493.
162. Yeyati P.L., van Heyningen V. Incapacitating the evolutionary capacitor: Hsp90 modulation of disease. Current Opinion in Genetics and Development 2008, 18:264-272.
163. Yin X., Zhang H., Lundgren K., Wilson L., Burrows F., Shores C.G. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. International Journal of Cancer 2010, 126:1216-1225.
164. Zhang H., Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. Journal of Molecular Medicine (Berlin) 2004, 82:488-499.
165. Zhang H., Chung D., Yang Y.C., Neely L., Tsurumoto S., Fan J., et al. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Molecular Cancer Therapeutics 2006, 5:1256-1264.
166. Zhang T., Hamza A., Cao X., Wang B., Yu S., Zhan C.G., et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Molecular Cancer Therapeutics 2008, 7:162-170.
167. Zhong Z., Simmons J., Timmermans P. Prevention and treatment of bortezemib-induced peripheral neuropathy by the Hsp90 inhibitor tanespimycin (KOS-953) in the rat. European Journal of Cancer Supplements 2008, 6:23.
168. Zoubeidi A., Zardan A., Beraldi E., Fazli L., Sowery R., Rennie P., et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Research 2007, 67:10455-10465.
169. Zuehlke A., Johnson J.L. Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 2010, 93:211-217.